The Leukemia & Lymphoma Society accelerated a portion of the final payment linked to the phase III study of CPX-351 (cytarabine:daunorubicin) liposome injection, Celator Pharmaceuticals’ lead product candidate, for the treatment of patients with high-risk acute myeloid leukemia.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
